Get started
Author

Marzia Cavalli

Observed names: CAVALLI, MARZIA, Cavalli, Marzia, M Cavalli, M. Cavalli
Institution: Ministry of Defence
ORCID: 0000-0002-2773-5483
Observed ORCID: 0000-0002-2773-5483
OpenAlex ID: A5037764279
Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances
2019 · Irene Della Starza, Sabina Chiaretti, et al. · Frontiers in Oncology · 124
PDF
Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial
2014 · Sara Galimberti, Stefano Luminari, et al. · Clinical Cancer Research · 119
PDF
Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913
2020 · Sabina Chiaretti, Monica Messina, et al. · Haematologica · 89
PDF
Comparative analysis between RQ‐PCR and digital‐droplet‐PCR of immunoglobulin/T‐cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia
2016 · Irene Della Starza, Vittorio Nunes, et al. · British Journal of Haematology · 69
PDF
Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
2019 · Ilaria Del Giudice, Sara Raponi, et al. · Frontiers in Oncology · 55
PDF
Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric‐like GIMEMA LAL ‐1308 trial
2020 · Anna Maria Testi, Martina Canichella, et al. · American Journal of Hematology · 45
PDF
Comparative analysis between RQ ‐ PCR and digital droplet PCR of BCL 2/ IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma
2017 · Marzia Cavalli, Lucia Anna De Novi, et al. · British Journal of Haematology · 43
Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia
2021 · Irene Della Starza, Vittorio Nunes, et al. · HemaSphere · 35
Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia
2019 · Irene Della Starza, Lucia Anna De Novi, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 29
Minimal residual disease monitoring in early stage follicular lymphoma can predict prognosis and drive treatment with rituximab after radiotherapy
2019 · Alessandro Pulsoni, Irene Della Starza, et al. · British Journal of Haematology · 21
PDF
Minimal residual disease (MRD) in non‐Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network
2019 · Irene Della Starza, Marzia Cavalli, et al. · Hematological Oncology · 14
Digital Droplet PCR Is a Reliable Tool to Improve Minimal Residual Disease Stratification in Adult Philadelphia-Negative Acute Lymphoblastic Leukemia
2022 · Irene Della Starza, Lucia A. De Novi, et al. · Journal of Molecular Diagnostics · 12
PDF
Comparison of two real‐time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real‐time quantitative polymerase chain reaction performance
2013 · Irene Della Starza, Marzia Cavalli, et al. · Hematological Oncology · 12
A case of late isolated ovarian relapse of acute lymphoblastic leukemia after an allogeneic stem cell transplant
2014 · Vittorio Nunes, Irene Della Starza, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 11
Ficoll‐hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis
2017 · E. Genuardi, D. Barbero, et al. · International Journal of Laboratory Hematology · 10
Ponatinib for the treatment of Ph-like acute lymphoblastic leukemia
2020 · Monia Lunghi, Andrea Patriarca, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 8
Digital-Droplet PCR, an Accurate Method for IG/TR PCR-MRD Stratification in Childhood Acute Lymphoblastic Leukemia
2018 · Irene Della Starza, Vittorio Nunes, et al. · Blood · 8
Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial
2024 · Alessandro Pulsoni, Simone Ferrero, et al. · The Lancet Haematology · 7
EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy
2019 · Alessandro Pulsoni, Maria Elena Tosti, et al. · Blood · 7
Comparison of different DNA extraction methods from peripheral blood cells: advice from the Fondazione Italiana Linfomi Minimal Residual Disease Network
2014 · Claudia Mannu, Anna Gazzola, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 7
Plagued by the Past, Pressed by the Present: A One Health Perspective on Yersinia pestis
2025 · Andrea Ciammaruconi, Maria Di Spirito, et al. · Biomedicines · 6
PDF
Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?
2023 · Giovanni Manfredi Assanto, Ilaria Del Giudice, et al. · Frontiers in Oncology · 6
PDF
Circulating cell‐free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre‐analytical biases
2022 · Roberta Soscia, Irene Della Starza, et al. · Hematological Oncology · 5
Next generation sequencing of multiple SARS-CoV-2 infections in the Omicron Era
2025 · Marzia Cavalli, Giulia Campoli, et al. · Scientific Reports · 4
A case of concomitant chronic lymphocytic leukaemia and hairy cell leukaemia evaluated for IGHV ‐D‐J rearrangements and BRAF ‐V600E mutation: lack of evidence for a common origin
2015 · Marzia Cavalli, Caterina Ilari, et al. · British Journal of Haematology · 4
PDF
Works count: 50
Citation count: 765
H-index: 12
I10-index: 15
Year
Topic
Type